Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers
European Thyroid Journal · 18.04.2024 · 13 (3)
DOI: 10.1530/etj-23-0227 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Thyroid Journal, erschienen am 18.04.2024. Verfasst von Abdul Rehman Syed und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Calgary, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality. For rare NTRK and RET fusion-positive metastatic, RAI-resistant thyroid cancers, variable success of re-induction of RAI avidity during treatment with NTRK or RET inhibitors has been reported. Case presentation and results We report two cases with RAI-resistant lung metastases treated with larotrectinib: an 83-year-old male presenting with an ETV6::NTRK3 fusion-positive tumor with the TERT promoter mutation c.-124C>T, and a 31-year-old female presenting with a TPR::NTRK1 fusion-positive tumor (and negative for TERT promoter mutation). Post larotrectinib treatment, diagnostic I-123 whole body scan revealed unsuccessful RAI-uptake re-induction in the TERT -positive tumor, with a thyroid differentiation score (TDS) of −0.287. In contrast, the TERT -negative tumor exhibited successful I-131 reuptake with a TDS of −0.060.
Conclusion
As observed for RAI-resistance associated with concurrent TERT and BRAF mutations, the co-occurrence of TERT mutations and NTRK fusions may also contribute to re-sensitization failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Calgary, Calgary, Alberta, Canada.
- Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Alberta, Canada.
- Alberta Precision Laboratories, Molecular Pathology Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Precision Oncology Hub Laboratory, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
- Department of Radiology, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada.
- Arnie Charbonneau Cancer Institute, Department of Medicine, Section of Endocrinology, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Abdul Rehman Syed, Markus Eszlinger, Ralf Paschke
Zitieren
APA
Syed, A. R., Gorana, A., Nohr, E., Yuan, X. K., Amin MASc, P., Ghaznavi, S., Lamb, D., McIntyre, J., Eszlinger, M., & Paschke, R. (2024). Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers. European Thyroid Journal, 13(3). https://doi.org/10.1530/etj-23-0227
Vancouver
Syed AR, Gorana A, Nohr E, Yuan XK, Amin MASc P, Ghaznavi S, et al. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers. European Thyroid Journal. 2024;13(3). doi:10.1530/etj-23-0227
BibTeX
@article{Syed2024,
author = {Syed, Abdul Rehman and Gorana, Aakash and Nohr, Erik and Yuan, Xiaoli-Kat and Amin MASc, Parthiv and Ghaznavi, Sana and Lamb, Debbie and McIntyre, John and Eszlinger, Markus and Paschke, Ralf},
title = {Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers},
journal = {European Thyroid Journal},
year = {2024},
volume = {13},
number = {3},
doi = {10.1530/etj-23-0227}
}
EUVIMED